GSK awaits FDA review of new shingles vaccine presentation
Shingrix in 2017 received US FDA approval to prevent shingles in adults aged 50 and older. Since 2021, it has been approved for use in immunocompromised patients aged 18 and up. GSK estimates around ...
GSK Nears $1 Billion Deal for Biotech Company IDRx
GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...
pharmaphorum27d
GSK first to sign ‘open research’ deal with London’s Crick Institute
GlaxoSmithKline (GSK) is to collaborate with the Francis Crick Institute, a new powerhouse of academic- and charity-funded biomedical research based in London. The new partnership is expected to ...
Bloomberg on MSN7mon
GSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay
Walmsley’s efforts ruffled feathers, and morale was initially low at GSK’s research hub in Stevenage, north of London. In an ...
EuropaWire8h
GSK Announces FDA Review of Convenient Prefilled Syringe for Shingrix Shingles Vaccine
GSK has announced that the FDA has accepted its application to review a prefilled syringe version of Shingrix, its shingles vaccine. This new ver ...
GSK Updates Shareholders on Voting Rights and Capital Structure
GSK plc announced an update regarding its total voting rights and capital for shareholders, as required by the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules. As of December ...
Daily3d
GSK bone cancer treatment gets USFDA Breakthrough Therapy Designation
London: GSK plc has announced that the US Food and Drug Administration (USFDA) has granted Breakthrough Therapy Designation ...
GSK settles vast majority of Zantac claims for $2.2 billion
GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac ...
Investing3d
FDA grants breakthrough status to GSK cancer drug
LONDON - GSK plc (LSE/NYSE: LON:GSK) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational drug GSK'227, aimed at treating adults with ...